Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: Embodiments of the disclosure concern methods and compositions for treating a subject with cancer, including overcoming resistance to a cancer drug using non-invasive radiotherapy frequency in combination with cancer drugs. In particular embodiments, radiofrequency therapy and cancer drugs in combination provide a synergistic benefit for cancer therapy. Use of radiofrequency therapy is an effective means to facilitate transport and perfusion of the cancer drugs in the subject.

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurized container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: Various embodiments of the present disclosure pertain to methods of optimizing a treatment efficacy of a biological system by tuning a property of the biological system through the addition of an optimizing agent to the biological system. The tuning can include: (a) determining a property parameter of the biological system; (b) selecting an optimizing agent to be added to the biological system based on the determined property parameter; and (c) adding the optimizing agent to the biological system. The optimizing agent can include a kosmotropic material. The biological system can include a tissue, such as a tumor. The methods of the present disclosure can be utilized to enhance the efficacy of various treatments, such as the heat treatment of a biological system exposed to a radiofrequency field. The methods of the present disclosure can also include a step of treating the biological system.

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfactant compound other than oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A method for preparing a ternary or higher zeotropic refrigerant mixture comprising components of different volatilities is described. The method comprises: mixing together the less volatile components of the mixture in a pre-blending process; and separately adding the most volatile component to the pre-blended mixture by pressure or mass flow control so that the desired initial liquid composition is attained. The liquid zeotropic refrigerant mixture that is prepared may be transferred from a container in which it is held to another container or to a piece of equipment that is to use the refrigerant mixture.

Abstract: A surfactant-free pharmaceutical composition is described. The composition consists essentially of: (a) a drug component consisting of salbutamol sulphate; and (b) a propellant component consisting essentially of 1,1-difluoroethane (R-152a). A method for preparing the pharmaceutical composition is also described. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A surfactant-free pharmaceutical composition is described. The composition consists essentially of: (a) a drug component consisting of salbutamol sulphate; and (b) a propellant component consisting essentially of 1,1-difluoroethane (R-152a). A method for preparing the pharmaceutical composition is also described. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A method for preparing a ternary or higher zeotropic refrigerant mixture comprising components of different volatilities is described. The method comprises: mixing together the less volatile components of the mixture in a pre-blending process; and separately adding the most volatile component to the pre-blended mixture by pressure or mass flow control so that the desired initial liquid composition is attained. The liquid zeotropic refrigerant mixture that is prepared may be transferred from a container in which it is held to another container or to a piece of equipment that is to use the refrigerant mixture.

Abstract: Heat transfer compositions are usable in their own right or are suitable as a replacement for existing refrigeration usages. The compositions possess a reduced Greenhouse Warming Potential, yet have a capacity and energy efficiency (which may be conveniently expressed as the “Coefficient of Performance”) ideally within 20% of the values of those attained using R-134a, and preferably within 10% or less (e.g. about 5%) of these values.

Abstract: Heat transfer compositions are usable in their own right or are suitable as a replacement for existing refrigeration usages. The compositions possess a reduced Greenhouse Warming Potential, yet have a capacity and energy efficiency (which may be conveniently expressed as the “Coefficient of Performance”) ideally within 20% of the values of those attained using R-134a, and preferably within 10% or less (e.g. about 5%) of these values.

Abstract: A process for preparing a second compound stereo-selectively is described. The process comprises reacting a substrate comprising at least one first compound with a reagent in the presence of a biological catalyst and a solvent comprising at least one (hydro)fluorocarbon so as to convert a first compound into the second compound.

Abstract: A process for treating a composition comprising one or more desired (hydro)halocarbons and one or more undesired sulphur containing impurities so as to reduce the concentration of at least one undesired sulphur containing impurity, the process comprising contacting the composition with an adsorbent comprising an acid stable molecular sieve having a pore size of from 2 to 10 ? and/or an activated carbon.

Abstract: A method of drying a fluid comprising a fluoropropene, which method comprises the step of contacting the fluid with a desiccant comprising molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. A heat transfer device comprising a heat transfer fluid comprising a fluoropropene, and a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. Preferably, the fluoropropene is R134yf or R-1225ye.

Abstract: A process for preparing a third compound stereo-selectively which process comprises reacting a substrate comprising a first enantiomeric compound with a racemisation catalyst to give a second enantiomeric compound, and concurrently reacting the second enantiomeric compound in the presence of a biological catalyst to give the third compound, wherein the process is performed in a solvent comprising at least one (hydro) fluorocarbon. The biological catalyst is preferably an enzyme. The substrate preferably comprises a racemate of the first and second enantiomeric compounds. The second enantiomeric compound may be reacted with a reagent, such as acyl donor, to form the third compound in the presence of the biological catalyst.